Skip to content

Multicenter randomized controlled clinical study of the method of benefiting qi and resolving blood stasis to prevent recurrence and metastasis of esophageal cancer after surgery

Multicenter randomized controlled clinical study of the method of benefiting qi and resolving blood stasis to prevent recurrence and metastasis of esophageal cancer after surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086556
Enrollment
Unknown
Registered
2024-07-05
Start date
2024-09-19
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative recurrence and metastasis of squamous esophageal cancer

Interventions

Control group:Placebo
Trial Group:Huage granules

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with positive lymph nodes in ypTNM stage III-IVa after radical esophageal cancer surgery who had completed neoadjuvant therapy for squamous esophageal cancer before surgery; Diagnostic criteria refer to the Diagnosis and Treatment Guidelines for Esophageal Cancer (2018 edition); Staging criteria: Using the UICC/AJCC TNM esophageal squamous cell carcinoma staging system (8th edition 2017); 2.Within 2 months of completion of postoperative chemotherapy or radiotherapy, or not receiving/intolerant of radiotherapy; Confirmed no recurrence or metastasis upon examination; 3.Consistent with the Chinese medicine diagnosis of qi deficiency and blood stasis patterns, refer to the national standard GB/T16751.2-1997. Qi deficiency syndrome has 2 main symptoms and 1 secondary symptom; Blood stasis syndrome has 2 main symptoms, or 1 main symptom+2 secondary symptoms; 4.KPS >= 70 points; 5.Age 18-80 years; agreed to participate in this study and signed an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Pregnant or nursing mothers; 2.Patients with known allergies to study medications; 3.Patients undergoing trials of other drugs; 4.Combined presence of serious non-neoplastic diseases and dysfunctions of the heart, liver, kidneys, cardiac and other major organs, active cerebrovascular lesions, uncontrolled infections and metabolic diseases; presence of other primary tumors; 5.The investigator determined that the patient was not suitable to participate in this study;

Design outcomes

Primary

MeasureTime frame
2-year DFS rate;

Secondary

MeasureTime frame
QLQ-C30;Esophageal Cancer Chinese Medicine Symptoms Score;Tests for blood, urine, stool routine, liver and kidney function, electrocardiogram, etc. Adverse reactions are classified according to NCI toxicity classification standards;

Countries

China

Contacts

Public ContactLiu Huaimin

Henan Cancer Hospital

13613829766@126.com+86 371 65588445

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026